Group 1 - The 420 Investor service, focused on cannabis stocks, has transitioned to Seeking Alpha, enhancing its coverage of the sector with model portfolios, videos, and written materials [1] - Organigram Global Inc. (OGI) was upgraded from Hold to Buy, while Village Farms (VFF) was downgraded from Sell to Strong Sell, indicating a shift in investment outlook for these companies [1] - Despite the upgrades, both stocks have declined in value over a 12-week period, prompting a reevaluation of Organigram's investment potential [1] Group 2 - Alan Brochstein, a pioneer in cannabis investment analysis, has been involved in the financial sector since 1986 and founded AB Analytical Services in 2007 to provide independent consulting [1] - Brochstein has managed the 420 Investor group since 2013, which closely monitors 19 cannabis stocks and provides timely investment news, earnings previews, and analyses [1] - The investing group features a model portfolio, 10 weekly videos with chart analysis, three weekly summary pieces, a monthly newsletter, and a chat function for investor inquiries [1]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, the company harvested over 28,000 kilograms of flower, representing a 43% year-over-year increase, driven by improving yields and ongoing refinements to nutrient programs [10] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][9] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by the success of vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while also looking at future international expansion opportunities [29][30] - The company aims to balance risk and growth opportunities in international markets while maintaining a strong focus on consumer needs and innovation [30] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management noted that Q1 results reflected strong year-over-year revenue and adjusted EBITDA growth, despite seasonal resets and operational pressures [16] - The company remains confident in its ability to deliver against full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals and expanding margins [24] - Management expressed optimism about international sales growth in fiscal 2026, despite a temporary decline in international volumes due to product specifications [12][13] Other Important Information - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for early screening of seedlings and reducing crop loss [11] - The company completed commissioning of its beverage line and began in-house production to support portfolio expansion [12] - The company is preparing for EU GMP certification and is working closely with regulators to address feedback received [13][48] Q&A Session Summary Question: Near-term opportunities and long-term initiatives - Management emphasized the importance of operational execution and cost management as short-term priorities, while focusing on international expansion as a long-term goal [29][30] Question: Insight on international volumes and flower issues - Management acknowledged stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact of the flower issues was approximately CAD 3.5 million on international revenue [36] Question: Recovery in the Canadian market - Management confirmed that distribution levels in BC have returned to normal and expressed confidence in recovering market share despite increased competition [42] Question: EU GMP certification timeline - Management stated they are working closely with regulators to address questions and are aiming for the fastest resolution possible, but could not provide a specific timeline [48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations and market conditions [52] Question: U.S. market strategy and regulatory environment - Management noted that the U.S. market is currently a small part of their business and emphasized a cautious approach to investments due to regulatory uncertainties [55][56] Question: Increased competition in pre-rolls - Management acknowledged competitive pressures across all categories, particularly in pre-rolls and vapes, and highlighted upcoming product innovations to address these challenges [60]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, international sales reached CAD 5 million, up 55% from Q1 fiscal 2025, despite a sequential decline due to a higher-than-expected proportion of flower that did not meet international specifications [12][17] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8][10] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][10] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by successful vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while balancing risk and growth opportunities in international markets [29][30] - The company aims to expand into international markets prudently while maintaining a strong focus on consumer needs and innovation [30][31] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC General Employees' Union strike and increased competition in vapes and pre-rolls on market share [6][15] - The company remains confident in its ability to deliver against previously issued guidance, expecting revenue to exceed CAD 300 million for the full year [24] - Management expressed optimism about international sales growth in fiscal 2026, despite temporary issues with product specifications [12][13] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase, driven by improved yields and ongoing refinements [10] - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for quicker screening of seedlings [11] - Total cash and short-term investments at quarter end were CAD 63 million, including CAD 7.6 million of unrestricted cash [23] Q&A Session Summary Question: Near-term opportunities and prioritization of initiatives - Management emphasized operational execution and cost base improvement as short-term priorities, while focusing on international expansion for long-term growth [29][30] Question: Insight on international volumes and flower issues - Management noted stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact on international revenue was about CAD 3.5 million due to out-of-spec flower [36] Question: Recovery in the Canadian market - Management confirmed recovery in BC distribution levels and acknowledged increased competition in vapes and pre-rolls, with plans for new innovations to regain market share [42][43] Question: EU GMP certification timeline - Management is working closely with regulators to address feedback and is unable to provide a specific timeline for certification [47][48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations [51][53] Question: U.S. market investment strategy - Management stated that the U.S. market is currently a minor part of the business, and they are being cautious with investments due to regulatory uncertainties [55][56]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, the integration of Motif, and higher international sales [16] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher yields and lower cultivation costs [16][17] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period [19] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period [19] Business Line Data and Key Metrics Changes - International sales for Q1 were CAD 5 million, up 51% over Q1 last year, despite a sequential decline due to higher-than-expected out-of-spec flower [16][12] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [7][6] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][7] Market Data and Key Metrics Changes - In Canada, the company held the number one market share position with 11.3% total share in Q1 and 11.7% over the past 12 months [5] - Market share in Quebec improved to the number three position with 9.9% for the quarter, driven by successful vape launches [6] - The company outperformed in several provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [7] Company Strategy and Development Direction - The company aims to focus on operational execution, cost base improvement, and margin enhancement in the short term, while pursuing international expansion in the long term [28] - The company is optimistic about the long-term growth of the cannabis industry and its ability to compete and lead as growth continues [5] - New product innovations, including SHRED Soda and SHRED Shots, are expected to enhance market competitiveness [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC labor strike and increased competition in vapes and pre-rolls but expressed confidence in recovering sales and maintaining adjusted gross margins [15][19] - The company is addressing temporary issues with international flower specifications and expects to return to normal operating parameters [12][34] - Management remains confident in delivering against full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals and expanding margins [23] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase [10] - The company is in the final phases of ERP implementation, with expectations for associated costs to roll off after the second quarter [18] - The company is preparing for EU GMP certification and is working closely with regulators to address feedback received [46] Q&A Session Summary Question: Near-term opportunities and long-term initiatives - Management emphasized the focus on operational execution and cost base improvement in the short term, while balancing future growth opportunities in international markets [27][28] Question: Insights on international volumes and flower issues - Management noted that stringent international flower requirements led to temporary issues, with an estimated CAD 3.5 million impact on international revenue [34][35] Question: Recovery in the Canadian market - Management confirmed that sales in BC have returned to traditional distribution levels and expressed confidence in addressing increased competition with new product launches [41][42] Question: EU GMP certification timeline - Management stated that they are working closely with regulators to resolve questions and are aiming for the fastest timeline possible, though no specific date can be provided [46] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations and market conditions [50][51] Question: U.S. market strategy and regulatory environment - Management highlighted that the U.S. market is currently a minor part of the business and emphasized a cautious approach to investment until regulatory clarity is achieved [54][55]

Investor Presentation December 31, 2025 CAUTIONARY STATEMENT This document is current as of December 31, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied ...

TABLE OF CONTENTS | Condensed Consolidated Interim Statements of Financial Position | 1 | | --- | --- | | Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss) | 2 | | Condensed Consolidated Interim Statements of Changes in Equity | 3 | | Condensed Consolidated Interim Statements of Cash Flows | 4 | | Notes to the Condensed Consolidated Interim Financial Statements | 5 – 16 | The accompanying notes are an integral part of these Condensed Consolidated Interim Financial State ...

Core Insights - Organigram Global Inc. reported strong year-over-year growth in Q1 Fiscal 2026, driven by Canadian market leadership and increasing international sales, alongside improved gross margins [1][2] Financial Performance - Net revenue increased by 49% to $63.5 million from $42.7 million in Q1 Fiscal 2025, primarily due to contributions from the Motif Labs acquisition and higher international sales [1][2] - Adjusted gross margin rose to $23.9 million, or 38% of net revenue, compared to $14.3 million, or 33%, in Q1 Fiscal 2025, attributed to operational efficiencies and higher flower yields [1][2] - Adjusted EBITDA reached $5.3 million, a 273% increase year-over-year, driven by higher recreational and international revenue [1][2] Operational Highlights - The company harvested 28,645 kilograms, a 43% increase compared to Q1 Fiscal 2025, achieved through nutrient and environmental enhancements [1] - Organigram launched its Collective Project and Fetch brands into Illinois and Wisconsin, expanding its U.S. retail footprint to 11 states [1] - The company achieved a proprietary genetic screening breakthrough for powdery mildew resistance, significantly reducing identification time [1] Market Position - Organigram holds the 1 market share in Canada for vapes, milled flower, and concentrates, and ranks 2 in pre-rolls and 3 in edibles and dried flower [1] - International sales reached $5.0 million, a 51% increase year-over-year, with expectations for continued growth [1][2] Balance Sheet and Liquidity - As of December 31, 2025, the company had total cash of $63.0 million, with total assets amounting to $530.7 million [2] - Total liabilities decreased by 24% to $161.2 million, while shareholders' equity increased by 6% to $369.5 million [2]

Core Viewpoint - Organigram Global Inc., Canada's leading cannabis company by market share, is set to report its earnings results for the first quarter of fiscal 2026 on February 10, 2026, before the market opens [1]. Group 1 - The earnings report will cover the period ending December 31, 2025 [1]. - A conference call will be held to discuss the results, scheduled for February 10, 2026, at 8:00 am Eastern Time [1].

Core Viewpoint - Organigram Global Inc. has announced an expansion of its innovation investment in Phylos Bioscience Inc., reinforcing its leadership in seed-based cannabis genetics [1] Group 1: Company Developments - Organigram is recognized as Canada's 1 cannabis company by market share [1] - The company has secured priority access to Phylos' autoflower genetics pipeline through an amended loan and product agreement [1] - The new agreement includes preferential economic terms and long-term benefits for Organigram [1]

Core Viewpoint - Organigram Global Inc. (OGI) has shown robust growth and operating leverage, leading to margin expansion, which justifies a buy rating initiated last August. The stock has increased by 31% since the rating due to solid Q4 performance [1]. Company Analysis - The company has demonstrated strong growth metrics, contributing to a favorable investment outlook. The increase in stock price reflects positive market sentiment and operational efficiency [1]. Market Trends - The analysis highlights the importance of thorough research and understanding of financial statements and market trends, which are critical for identifying undervalued investment opportunities in mid and small-cap companies [1].